These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22332713)

  • 21. Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients.
    Barbano R; Pasculli B; Coco M; Fontana A; Copetti M; Rendina M; Valori VM; Graziano P; Maiello E; Fazio VM; Parrella P
    Sci Rep; 2015 Dec; 5():18592. PubMed ID: 26690267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
    Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
    McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
    Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing.
    Marchant J; Mange A; Larrieux M; Costes V; Solassol J
    BMC Cancer; 2014 Jul; 14():519. PubMed ID: 25037456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.
    How-Kit A; Lebbé C; Bousard A; Daunay A; Mazaleyrat N; Daviaud C; Mourah S; Tost J
    Anal Bioanal Chem; 2014 Sep; 406(22):5513-20. PubMed ID: 24969466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues.
    Chat-Uthai N; Vejvisithsakul P; Udommethaporn S; Meesiri P; Danthanawanit C; Wongchai Y; Teerapakpinyo C; Shuangshoti S; Poungvarin N
    PLoS One; 2018; 13(6):e0198795. PubMed ID: 29879227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.
    Mourah S; Denis MG; Narducci FE; Solassol J; Merlin JL; Sabourin JC; Scoazec JY; Ouafik L; Emile JF; Heller R; Souvignet C; Bergougnoux L; Merlio JP
    PLoS One; 2015; 10(3):e0120232. PubMed ID: 25789737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.
    Richter A; Grieu F; Carrello A; Amanuel B; Namdarian K; Rynska A; Lucas A; Michael V; Bell A; Fox SB; Hewitt CA; Do H; McArthur GA; Wong SQ; Dobrovic A; Iacopetta B
    Sci Rep; 2013; 3():1659. PubMed ID: 23584600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
    Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
    Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
    Cheng LY; Haydu LE; Song P; Nie J; Tetzlaff MT; Kwong LN; Gershenwald JE; Davies MA; Zhang DY
    Sci Rep; 2021 Apr; 11(1):9043. PubMed ID: 33907234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry.
    Dinges HC; Capper D; Ritz O; Brüderlein S; Marienfeld R; von Deimling A; Möller P; Lennerz JK
    Appl Immunohistochem Mol Morphol; 2015; 23(5):382-8. PubMed ID: 25611237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
    Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
    Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF mutation testing in solid tumors: a methodological comparison.
    Weyant GW; Wisotzkey JD; Benko FA; Donaldson KJ
    J Mol Diagn; 2014 Sep; 16(5):481-5. PubMed ID: 25132480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
    Rubinstein JC; Sznol M; Pavlick AC; Ariyan S; Cheng E; Bacchiocchi A; Kluger HM; Narayan D; Halaban R
    J Transl Med; 2010 Jul; 8():67. PubMed ID: 20630094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.